Form 4 for GYRE GYRE THERAPEUTICS, INC.
Accepted 2021-07-02 00:00:00 ET · period of report 2021-06-09 · accession 0001209191-21-044691 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-02 | 2021-07-01 | GYRE | Ling Geoffrey M.D. | Dir | A - Grant | $0.00 | +2,713 | 16.1K | +20% | $0 |
| D | 2021-07-02 | 2021-06-09 | GYRE | Ling Geoffrey M.D. | Dir | A - Grant | $0.00 | +14.0K | 14.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-01 | A | A | 2,713 | $0.00 | 16,077 | D | — | — | (F1) Represents shares of common stock received in lieu of fees. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-06-09 | A | A | 14,000 | $0.00 | 14,000 | D | $4.55 · — to 2031-06-09 | 14,000 Common Stock | (F2) 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. |